ICU Medical (NASDAQ:ICUI – Get Free Report) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Sunday.
Several other research firms have also commented on ICUI. Piper Sandler increased their target price on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a report on Thursday, January 22nd. Finally, KeyCorp raised their target price on ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.67.
Read Our Latest Research Report on ICUI
ICU Medical Stock Up 2.0%
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Arizona State Retirement System boosted its holdings in shares of ICU Medical by 1.3% in the third quarter. Arizona State Retirement System now owns 6,903 shares of the medical instruments supplier’s stock valued at $828,000 after acquiring an additional 91 shares during the period. Oregon Public Employees Retirement Fund raised its position in ICU Medical by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock valued at $803,000 after purchasing an additional 100 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. Lido Advisors LLC grew its position in ICU Medical by 4.5% during the 4th quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock worth $354,000 after purchasing an additional 106 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in ICU Medical by 4.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,459 shares of the medical instruments supplier’s stock worth $325,000 after purchasing an additional 107 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company’s stock.
About ICU Medical
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
- Five stocks we like better than ICU Medical
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
